Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.

Cummins KC, Cheng MP, Kubiak DW, Davids MS, Marty FM, Issa NC.

Leuk Lymphoma. 2018 Jul 24:1-4. doi: 10.1080/10428194.2018.1485913. [Epub ahead of print] No abstract available.

PMID:
30037292
2.

The rise of apoptosis: targeting apoptosis in hematologic malignancies.

Valentin R, Grabow S, Davids MS.

Blood. 2018 Sep 20;132(12):1248-1264. doi: 10.1182/blood-2018-02-791350. Epub 2018 Jul 16. Review.

PMID:
30012635
3.

Statins enhance efficacy of venetoclax in blood cancers.

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaaq1240. doi: 10.1126/scitranslmed.aaq1240.

PMID:
29899021
4.

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.

PMID:
29895707
5.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.

PMID:
29715056
6.

Risk of hepatitis B virus reactivation in patients treated with ibrutinib.

Hammond SP, Chen K, Pandit A, Davids MS, Issa NC, Marty FM.

Blood. 2018 Apr 26;131(17):1987-1989. doi: 10.1182/blood-2018-01-826495. Epub 2018 Feb 28. No abstract available.

PMID:
29490923
7.

Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study.

Flowers CR, Nabhan C, Kay NE, Mato A, Lamanna N, Farber CM, Davids MS, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP.

Leuk Lymphoma. 2018 Feb 7:1-9. doi: 10.1080/10428194.2018.1427860. [Epub ahead of print]

PMID:
29415595
8.

Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.

Soiffer RJ, Davids MS, Chen YB.

Blood. 2018 Mar 8;131(10):1073-1080. doi: 10.1182/blood-2017-10-752154. Epub 2018 Jan 22. Review.

PMID:
29358177
9.

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.

Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):114-124.e2. doi: 10.1016/j.clml.2017.11.010. Epub 2017 Dec 6.

10.

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.

Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS.

Blood. 2018 Apr 12;131(15):1704-1711. doi: 10.1182/blood-2017-06-788133. Epub 2018 Jan 5.

11.

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.

Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, Mato A, Nabhan C, Kiselev P, Swern AS, Flick ED, Sullivan K, Sharman JP, Flowers CR.

Blood Adv. 2017 Nov 28;1(25):2433-2443. doi: 10.1182/bloodadvances.2017011262. eCollection 2017 Nov 28.

12.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC.

Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.

PMID:
29246803
13.

Safety profiles of novel agent therapies in CLL.

Ahn IE, Davids MS.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):354-357. doi: 10.1182/asheducation-2017.1.354. Review.

PMID:
29222278
14.

How should we sequence and combine novel therapies in CLL?

Davids MS.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):346-353. doi: 10.1182/asheducation-2017.1.346. Review.

PMID:
29222277
15.

Targeting BCL-2 in B-cell lymphomas.

Davids MS.

Blood. 2017 Aug 31;130(9):1081-1088. doi: 10.1182/blood-2017-04-737338. Epub 2017 Jul 19. Review.

16.

IGHV mutational status testing in chronic lymphocytic leukemia.

Crombie J, Davids MS.

Am J Hematol. 2017 Dec;92(12):1393-1397. doi: 10.1002/ajh.24808. Epub 2017 Jul 29. Review.

PMID:
28589701
17.

A complex case of ibrutinib treatment for a CLL patient on haemodialysis.

Aw A, Hellman JM, Birner A, Davids MS.

Br J Haematol. 2018 Jun;181(6):854-857. doi: 10.1111/bjh.14718. Epub 2017 May 16. No abstract available.

PMID:
28508526
18.

Venetoclax for the treatment of patients with chronic lymphocytic leukemia.

Crombie J, Davids MS.

Future Oncol. 2017 Jun;13(14):1223-1232. doi: 10.2217/fon-2017-0031. Epub 2017 May 11.

PMID:
28492339
19.

Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia.

Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr.

Eur J Heart Fail. 2017 May;19(5):682-685. doi: 10.1002/ejhf.806. No abstract available.

20.

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.

Nabhan C, Mato A, Flowers CR, Grinblatt DL, Lamanna N, Weiss MA, Davids MS, Swern AS, Bhushan S, Sullivan K, Flick ED, Kiselev P, Sharman JP.

BMC Cancer. 2017 Mar 16;17(1):198. doi: 10.1186/s12885-017-3176-x.

Supplemental Content

Loading ...
Support Center